Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial With Pemetrexed Plus Cisplatin as First Line Chemotherapy for Advanced Non - Small Cell Lung Cancer (NSCLC) Patients With Measurable Asymptomatic Brain Metastasis (GFPC 07-01/METAL).

NCT00744900 is registered in ClinicalTrials.gov with University Hospital, Brest as lead sponsor.

NCT NCT00744900
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00744900 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial With Pemetrexed Plus Cisplatin as First Line Chemotherapy for Advanced Non - Small Cell Lung Cancer (NSCLC) Patients With Measurable Asymptomatic Brain Metastasis (GFPC 07-01/METAL).
Lead sponsor
University Hospital, Brest
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2008
Completion date
Not reported
Enrollment
45 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer